Scientists and doctors are getting much better at developing treatments for cancer. More than 18 million people with a history of cancer were alive in the U.S. at the beginning of 2022, up from just 3 million in 1971, according to the 14th edition of the American Association for Cancer Research (AACR) Cancer Progress Report. And that number is expected to rise to 26 million by 2040.
Researchers from Sichuan Baili Pharmaceutical Co. Ltd. and Systimmune Inc. presented preclinical data for the novel CD33-targeting antibody-drug conjugate (ADC) being evaluated for the treatment of hematologic malignancies.
α-Fetoprotein (AFP) is a tumor-associated antigen and an ideal target for T-cell receptor T-cell (TCR-T) therapy. While the safety of AFP-targeting TCR-T products has been previously demonstrated in early clinical trials, the efficacy of these cell therapies is still modest, warranting further research.
